Miransertib
- Generic Name
- Miransertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H24N6
- CAS Number
- 1313881-70-7
- Unique Ingredient Identifier
- T1DQI1B52Y
- Background
Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
- Conditions
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT04980872
- Locations
- 🇺🇸
Texas Children's Hospital ( Site 0104), Houston, Texas, United States
🇺🇸Seattle Children's Hospital ( Site 0103), Seattle, Washington, United States
🇮🇹Ospedale Pediatrico Bambino Gesù-Centro Trials ( Site 0087), Rome, Roma, Italy
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Registration Number
- NCT03317366
Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)
- Conditions
- Interventions
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Target Recruit Count
- 50
- Registration Number
- NCT03094832
- Locations
- 🇺🇸
Boston Children's Hospital ( Site 0089), Boston, Massachusetts, United States
🇺🇸Seattle Childrens Hospital ( Site 0103), Seattle, Washington, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0101), Chicago, Illinois, United States
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
- Conditions
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Target Recruit Count
- 120
- Registration Number
- NCT01473095
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.